EP4061370A1 - Composition de granulés comprenant de la propivérine ou un sel pharmaceutiquement acceptable de celle-ci - Google Patents

Composition de granulés comprenant de la propivérine ou un sel pharmaceutiquement acceptable de celle-ci

Info

Publication number
EP4061370A1
EP4061370A1 EP20889321.4A EP20889321A EP4061370A1 EP 4061370 A1 EP4061370 A1 EP 4061370A1 EP 20889321 A EP20889321 A EP 20889321A EP 4061370 A1 EP4061370 A1 EP 4061370A1
Authority
EP
European Patent Office
Prior art keywords
pellet
composition according
propiverine
pellet composition
acid
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
EP20889321.4A
Other languages
German (de)
English (en)
Other versions
EP4061370A4 (fr
Inventor
Fatih Sunel
Ediz Yildirim
Gulcin TOK
Bulent DEMIR
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Sanovel Ilac Sanayi ve Ticaret AS
Original Assignee
Sanovel Ilac Sanayi ve Ticaret AS
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Sanovel Ilac Sanayi ve Ticaret AS filed Critical Sanovel Ilac Sanayi ve Ticaret AS
Publication of EP4061370A1 publication Critical patent/EP4061370A1/fr
Publication of EP4061370A4 publication Critical patent/EP4061370A4/fr
Pending legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2072—Pills, tablets, discs, rods characterised by shape, structure or size; Tablets with holes, special break lines or identification marks; Partially coated tablets; Disintegrating flat shaped forms
    • A61K9/2077—Tablets comprising drug-containing microparticles in a substantial amount of supporting matrix; Multiparticulate tablets
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/445—Non condensed piperidines, e.g. piperocaine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A61K9/1605—Excipients; Inactive ingredients
    • A61K9/1629—Organic macromolecular compounds
    • A61K9/1635—Organic macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyvinyl pyrrolidone, poly(meth)acrylates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/10—Drugs for disorders of the urinary system of the bladder
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A61K9/1605—Excipients; Inactive ingredients
    • A61K9/1629—Organic macromolecular compounds
    • A61K9/1652—Polysaccharides, e.g. alginate, cellulose derivatives; Cyclodextrin

Definitions

  • the present invention relates to a pellet composition comprising propiverine or a pharmaceutically acceptable salt thereof for oral administration which is formulated as modified release.
  • Overactive bladder (OAB) and the related condition of urge urinary incontinence represent the other major disorder of the storage function. They are characterized by a frequent need to void (frequency), with an intense urge to do so (urgency) and a need to void during the night (nocturia). Contrary to stress urinary incontinence, OAB and urge incontinence are not associated with urethral sphincter control but rather involves disturbances in bladder functions and the regulation thereof.
  • antimuscarinic agents which exert their effects at muscarinic receptors and suppress or diminish the intensity of involuntary detrusor muscle contractions, are the first-choice pharmacotherapy for OAB, and may be the only therapy available whose efficacy is not in question.
  • Propiverine hydrochloride is an extensively studied antimuscarinic and calcium channel blocker agent.
  • Propiverine is one of the most frequently prescribed antimuscarinic drugs used for the treatment of overactive bladder and urinary incontinence.
  • the chemical name of propiverine is (l-methyl-4-piperidyl diphenylpropoxyacetate) and it is a benzylic acid derivative as shown in Formula I.
  • Formula I Propiverine is a BCS (Biopharmaceutical Classification System) Class III drug, which exhibits low permeability and high solubility.
  • typical anticholinergic side effects like and accommodation disorders have to be accepted with a rapid increase in the blood level. Therefore, these side effects limit the amount of the possible unit dose of non-modified, rapidly releasing dosage forms to 10-20 mg.
  • Propiverine in the form of its hydrochloride salt is currently marketed under the trade names Mictonorm® / Detrunorm®/ Proprinorm® by Apogepha Arzneistoff GmbH in two different dosage forms as immediate -release (IR) and modified-release (MR).
  • IR immediate -release
  • MR modified-release
  • TR 2012/11270 patent application discloses an oral pharmaceutical composition comprising propiverine or a pharmaceutically acceptable salt thereof as an anticholinergic active agent.
  • composition comprising propiverine or a pharmaceutically acceptable salt thereof which overcomes the above described problems in the prior art and has additive advantages over them.
  • the main object of the present invention is to provide a composition comprising propiverine or a pharmaceutically acceptable salt thereof having high stability by the help of using a pellet composition.
  • modified release refers to any pharmaceutical formulation that maintain constant levels of a drug in the patient's bloodstream by releasing the drug over an extended period of time. Modified release is formulated to release the active ingredient gradually and predictably over a 12-hour to 24-hour period.
  • propiverine or a pharmaceutically acceptable salt thereof are thus not suitable for the realization of a modified release formulation.
  • propiverine or a pharmaceutically acceptable salt thereof especially propiverine hydrochloride, is sensitive to environmental conditions and excipients used. Therefore, the steps and polymers employed to make modified-release are important in the present invention.
  • Pellets can be blended to deliver incompatible active agents.
  • the reproducibility of the pellet formulations is also much better than the reproducibility of the single-unit dosage forms. They are suitable systems for film coating with respect to the low surface area-volume ratios.
  • one of the advantageous properties of the pellet formulations is being good resistance to external factors such as moisture, air and light.
  • pellets have excellent flow properties. Considering all these advantages, the pellet form is best for use in propiverine-containing formulation.
  • a pellet composition comprises propiverine or a pharmaceutically acceptable salt thereof, wherein the pellet composition is formulated as modified release.
  • propiverine or a pharmaceutically acceptable salt thereof is propiverine hydrochloride.
  • the amount of propiverine hydrochloride is present between 5.0% and 40.0%, 7.0% and 35.0%, 10.0% and 30.0%, 11.0% and 25.0%, 12.0% and 20.0%, 12.0% and 18.0% by weight of the pellet.
  • propiverine hydrochloride is also present outside the pellet.
  • the amount of propiverine hydrochloride is present between 1.0% and 30.0%, 1.0% and 25.0%, 1.0% and 20.0%, 1.0% and 15.0%, 1 .0% and 10.0%, 1.0% and 6.0% by weight of the total composition.
  • the pellets further comprises at least one release modifying agent.
  • Suitable release modifying agent is selected from the group comprising poly(methacrylic acid-co-methylmethacrylate), poly(methyl acrylate-co-methyl methacrylate-co-methacrylic acid), ethyl cellulose, methyl cellulose, hydroxypropylmethylcellulose, cellulose acetate, cellulose acetate phthalate, cellulose acetate trimellitate, hydroxypropyl methylcellulose phthalate, hydroxypropyl methylcellulose acetate succinate, poly(methacrylic acid-co- ethylacrylate), polyvinylchloride, polyvinyl acetate phthalate, poly(vinylpyrrolidone-co- vinylacetate), silicone elastomers, shellac, zein, rosin esters or mixtures thereof.
  • the amount of the release modifying agent is between 1.0% and 25.0%, 2.0% and 20.0%, 3.0% and 15.0%, 5.0% and 10.0% by weight of the pellet.
  • the amount of the release modifying agent is between 0.5% and 10.0%, 1.0% and 8.0%, 1.0% and 6.0%, 1.0% and 4.0% by weight of the total composition.
  • the release modifying agent is poly(methacrylic acid-co-methylmethacrylate) 1 :2 (Eudragit S 100) or poly(methacrylic acid-co- methylmethacrylate) 1 :1 (Eudragit L 100) or poly(methyl acrylate-co-methyl methacrylate-co- methacrylic acid) 7:3:1 (Eudragit FS 30 D) , they can be used together or separately.
  • the optimum amounts of the excipients for example the composition of the corresponding mixtures depend on several factors, like for example the desired retarding effect, the kind of the release modifying agent having their specific solubility and permeability, and the ratio of acidic substance to active agent propiverine. These parameters vary completely independently from each other and are of essential importance for the controlled and long- lasting, modified release of the propiverine.
  • the preferred dosage forms are tablets or capsules filled with pellets as these are more convenient and easier to administer.
  • the form of the composition is a tablet.
  • Pellet is located within a tablet.
  • the tablet further comprises at least one pharmaceutically acceptable excipient which is selected from the group comprising fillers, pH adjusters, binders, disintegrants, plasticizers, lubricants, glidants, suspending agents, permeability enhancing agents or mixtures thereof.
  • Suitable fillers are selected from the group comprising neutral microcrystalline cellulose pellets, lactose, microcrystalline cellulose, ammonium alginate, calcium carbonate, calcium phosphate, calcium phosphate dehydrate, calcium sulfate, cellulose, cellulose acetate, compressible sugar, dextrates, dextrin, dextrose, erythritol, ethylcellulose, fructose, isomalt, mannitol, magnesium carbonate, magnesium oxide, maltodextrin, maltose, medium chain triglycerides, polydextrose, polymethacrylates, sodium alginate, sodium chloride, sorbitol, starch, sucrose, sugar spheres, sulfobutylether beta-cyclodextrin, tragacanth, trehalose, polysorbate 80, xylitol or mixtures thereof.
  • the amount of the fillers is between 5.0% and 35.0%, 7.0% and 30.0%, 9.0% and 25.0%, 10.0% and 20.0% by weight of the pellet.
  • the amount of the fillers is between 50.0% and 87.0%, 55.0% and 84.0%, 60.0% and 80.0%, 65.0% and 75.0% by weight of the total composition.
  • the filler is neutral microcrystalline cellulose pellets or lactose or microcrystalline cellulose or mixtures thereof.
  • fillers should be as inert as possible to prevent them from interacting with propiverine hydrochloride, they should serve only as a carrier to enable propiverine hydrochloride.
  • neutral microcrystalline cellulose pellets support the formulation, such as by improving propiverine hydrochloride solubility, improving dissolution and enhancing stability. So, neutral microcrystalline cellulose pellets are used in pellets as fillers.
  • compositions comprise at least one pharmaceutically acceptable organic or inorganic acid having a pKa value of less than 6.65.
  • Acidic compound is used to provide pH-independent solubility of propiverine and the salts thereof by forming aquasiionpair of propiverine and acid, leading to a sufficient release in the whole intestinal tract, independent from the kind of the propiverine salt present.
  • Suitable pH adjusters are selected from the group comprising citric acid, aluminum potassium sulfate, potassium carbonate, anhydrous sodium dihydrogen phosphate, dibasic potassium sulfate, calcium carbonate, nicotinic acid, dilute hydrochloric acid, glacial acetic acid, lactic acid, maleic acid, monobasic potassium phosphate, phosphoric acid, adipic acid, sodium acetate, sodium bicarbonate, sodium carbonate, sodium citrate, sodium dihydrogen phosphate dihydrate, tartaric acid, tribasic sodium phosphate or mixtures thereof.
  • the weight ratio of acidic substance (pH adjusters) to propiverine or a pharmaceutically acceptable salt thereof is between 0.1 and 6.0, 0.5 and 5.0, 1.0 and 4.0 or preferably between 1.5 and 3.5.
  • the amount of the pH adjusters is between 30.0% and 60.0%, 32.0% and 50.0%, 35.0% and 45.0% by weight of the pellet.
  • the amount of the pH adjusters is between 1 .0% and 30.0%, 3.0% and 25.0%, 5.0% and 20.0%, 7.0% and 15.0% by weight of the total composition.
  • the pH adjuster is citric acid.
  • Suitable binders are selected from the group comprising polyvinylpyrrolidone, sugars, glycose syrup, natural gums, gelatin, agar, alginates, co-povidone, sodium alginate, guar gum, starch mucilage, acacia mucilage, bentonite, laponit, cetostearyl alcohol, polydextrose, polyethylene oxide, pectin, aluminum hydroxide, hyaluronic acid or mixtures thereof.
  • the amount of the binders is between 1 .0% and 25.0%, 3.0% and 16.0%, 4.0% and 10.0% by weight of the pellet.
  • the amount of the binders is between 1 .0% and 25.0%, 3.0% and 16.0%, 4.0% and 10.0% by weight of the total composition.
  • the binder is polyvinylpyrrolidone.
  • Suitable plasticizers are selected from the group comprising triethyl citrate, polyethylene glycols, triacetin, tributyl citrate, chlorobutanol, dibutyl phthalate, dibutyl sebacate, dimethyl phthalate, glycerin, mannitol, petrolatum and lanolin alcohols or mixtures thereof.
  • the amount of the plasticizers is between 0.05% and 5.0%, 0.5% and 3.0% by weight of the pellet.
  • the amount of the plasticizers is between 0.01% and 5.0%, 0.05% and 3.0% by weight of the total composition.
  • the plasticizer is triethyl citrate.
  • Suitable disintegrants are selected from the group comprising croscarmellose sodium, carboxymethyl cellulose, sodium carboxymethyl cellulose, crosslinked sodium carboxymethyl cellulose, calcium carboxymethyl cellulose, sodium carboxymethyl starch or mixtures thereof.
  • the amount of the disintegrants is between 1.0% and 15.0% by weight of the total composition.
  • Suitable lubricants are selected from the group comprising magnesium stearate, sodium stearyl fumarate, polyethylene glycol, sodium lauryl sulphate, magnesium lauryl sulphate, fumaric acid, glyceryl palmitostearate, hydrogenated natural oils, zinc stearate, calcium stearate, silica, talc, stearic acid, polyethylene glycol, paraffin or mixtures thereof.
  • the lubricant is magnesium stearate.
  • the amount of the lubricants is between 0.05% and 5.0%, 0.5% and 3.0% by weight of the total composition.
  • the lubricant is magnesium stearate.
  • Suitable glidants are selected from the group comprising colloidal silicon dioxide, water soluble excipient, hydrophilic polymers, silicon dioxide or mixtures thereof.
  • the amount of the glidants is between 0.05% and 5.0%, 0.5% and 3.0% by weight of the total composition.
  • the glidant is colloidal silicon dioxide.
  • Suitable suspending agents are selected from the group comprising talc, xanthan gum, guar gum, glycerol, polyvinyl alcohol, polyvinyl pyrrolidone, polyethylene oxide, cellulose derivatives, ethylcellulose, hydroxyethylcellulose, hydroxyethylmethylcellose or mixtures thereof.
  • the suspending agent is talc.
  • the amount of the suspending agents is between 5.0% and 25.0%, 8.0% and 20.0%, 9.0% and 17.0% by weight of the pellet.
  • the amount of the suspending agents is between 0.5% and 10.0%, 1 .0% and 8.0% by weight of the total composition.
  • Suitable permeability enhancing agents are selected from the group comprising ethyl acrylate, methyl methacrylate and a low content of methacrylic acid ester, ethanol, isopropyl alcohol, propylene glycol or mixtures thereof.
  • Propiverine is a BCS (Biopharmaceutical Classification System) Class III drug, which exhibits low permeability. So, it is important to permeability enhancing agents used.
  • BCS Biopharmaceutical Classification System
  • the amount of the permeability enhancing agents is between 0.5% and 6.0%, 1 .0% and 4.0% by weight of the pellet.
  • the amount of the permeability enhancing agents is between 0.05% and 4.0%, 0.1% and 2.0% by weight of the total composition.
  • the permeability enhancing agent is ethyl acrylate or methyl methacrylate or a low content of methacrylic acid ester (Eudragit RS or Eudragit RL) or mixtures thereof.
  • Said pharmaceutical composition is compressed into tablets after direct compression or dry granulation or wet granulation.
  • the tablets may be film-coated in a conventional manner.
  • the pellets comprises;
  • the tablet comprises;
  • Ethyl acrylate or methyl methacrylate or a low content of methacrylic acid ester (Eudragit RS or Eudragit RL)
  • EXAMPLE 1 A TABLET COMPRISING PELLETS HAVING PROPIVERINE HYDROCHLORIDE
  • EXAMPLE 2 A TABLET COMPRISING PELLETS HAVING PROPIVERINE HYDROCHLORIDE Process for example for 1 or 2;
  • pellet For pellet: a) Adding propiverine hydrochloride, neutral microcrystalline cellulose pellet, citric acid, polyvinylpyrrolidone, lactose, Eudragit RS, Eudragit RL, Eudragit S 100, Eudragit L 100, Eudragit FS 30 D, triethylcitrate, talc, magnesium stearate in homogenizer and mixing, b) Then, obtained pellets with fluidized bed dryer,
  • Steps after obtained pellet c) Granulating granulation solution comprising polyvinylpyrrolidone with microcrystalline cellulose Ph101 , d) Sieving and drying the granules until the humidity is less than 0.3%, e) Again, sieving the granules, f) Adding colloidal silicon dioxide and prepared pellets and mixing g) Adding magnesium stearate and mixing, h) Then, pressing to form tablet, i) Coating tablets with coating agents.
  • EXAMPLE 3 A TABLET COMPRISING PELLETS HAVING PROPIVERINE HYDROCHLORIDE Process for example for 3;
  • pellet For pellet: a) Adding propiverine hydrochloride, neutral microcrystalline cellulose pellet, citric acid, polyvinylpyrrolidone, lactose, Eudragit RS, Eudragit RL, Eudragit S 100, Eudragit L 100, Eudragit FS 30 D, triethylcitrate, talc, magnesium stearate in homogenizer and mixing, b) Then, obtained pellets with fluidized bed dryer,
  • Steps after obtained pellet c) Granulating granulation solution comprising polyvinylpyrrolidone with microcrystalline cellulose Ph101 and croscarmellose sodium and propiverine hydrochloride, d) Sieving and drying the granules until the humidity is less than 0.3%, e) Again, sieving the granules, f) Adding colloidal silicon dioxide and prepared pellets and mixing g) Adding magnesium stearate and mixing, h) Then, pressing to form tablet, i) Coating tablets with coating agents.

Landscapes

  • Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • General Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Epidemiology (AREA)
  • Urology & Nephrology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Preparation (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)

Abstract

La présente invention concerne une composition de granulés comprenant de la propivérine ou un sel pharmaceutiquement acceptable de celle-ci pour administration orale qui se présente sous la forme d'une formulation à libération modifiée.
EP20889321.4A 2019-11-19 2020-10-27 Composition de granulés comprenant de la propivérine ou un sel pharmaceutiquement acceptable de celle-ci Pending EP4061370A4 (fr)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
TR2019/18013A TR201918013A2 (tr) 2019-11-19 2019-11-19 Propi̇veri̇n veya propi̇veri̇ni̇n farmasöti̇k olarak kabul edi̇lebi̇li̇r bi̇r tuzunu i̇çeren pellet kompozi̇syonu
PCT/TR2020/050998 WO2021101481A1 (fr) 2019-11-19 2020-10-27 Composition de granulés comprenant de la propivérine ou un sel pharmaceutiquement acceptable de celle-ci

Publications (2)

Publication Number Publication Date
EP4061370A1 true EP4061370A1 (fr) 2022-09-28
EP4061370A4 EP4061370A4 (fr) 2023-08-02

Family

ID=75980701

Family Applications (1)

Application Number Title Priority Date Filing Date
EP20889321.4A Pending EP4061370A4 (fr) 2019-11-19 2020-10-27 Composition de granulés comprenant de la propivérine ou un sel pharmaceutiquement acceptable de celle-ci

Country Status (4)

Country Link
EP (1) EP4061370A4 (fr)
CA (1) CA3162408A1 (fr)
TR (2) TR201918013A2 (fr)
WO (1) WO2021101481A1 (fr)

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2023080856A1 (fr) * 2021-11-03 2023-05-11 Santa Farma Ilac Sanayii A.S. Composition pharmaceutique de chlorhydrate de propivérine à enrobage entérique
WO2023128906A1 (fr) * 2021-12-30 2023-07-06 Santa Farma Ilac Sanayii A.S. Libération de compositions de propivérine dans des conditions gastriques

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE10149674A1 (de) * 2001-10-09 2003-04-24 Apogepha Arzneimittel Gmbh Orale Darreichungsformen für Propiverin oder seinen pharmazeutisch annehmbaren Salzen mit verlängerter Wirkstoffreisetzung
ITMI20061024A1 (it) * 2006-05-25 2007-11-26 Eurand Pharmaceuticals Ltd Pellet a base di acido lipoico
TWI519322B (zh) * 2008-04-15 2016-02-01 愛戴爾製藥股份有限公司 包含弱鹼性藥物及控制釋放劑型之組合物
CN102579404A (zh) 2012-01-17 2012-07-18 广州科的信医药技术有限公司 一种盐酸丙哌维林缓释胶囊及其制备方法

Also Published As

Publication number Publication date
WO2021101481A1 (fr) 2021-05-27
TR202016210A2 (tr) 2021-06-21
EP4061370A4 (fr) 2023-08-02
CA3162408A1 (fr) 2021-05-27
TR201918013A2 (tr) 2021-06-21

Similar Documents

Publication Publication Date Title
CA2595033C (fr) Formulations pharmaceutiques gastroresistantes a base de rifaximine
JP2011513391A (ja) ミコフェノラートを含有する徐放性医薬組成物およびその方法
US11975103B2 (en) Compositions of midodrine and methods of using the same
US9011912B2 (en) Extended-release oral dosage forms for poorly soluble amine drugs
US20210220281A1 (en) Oral pharmaceutical compositions of mesalazine
WO2006011159A2 (fr) Composition pharmaceutique stabilisee contenant du sodium de rabeprazole presentant une biodisponibilite amelioree
US6270799B1 (en) Medicament formulation with a controlled release of an active agent
KR20090029830A (ko) 소장 내에서 활성성분의 방출이 제어되는 경구투여용 약제학적 조제물 및 그의 제조방법
RU2010109408A (ru) Композиции с пролонгированным высвобождением, включающие микофенолят натрия, и их действия
EP4061370A1 (fr) Composition de granulés comprenant de la propivérine ou un sel pharmaceutiquement acceptable de celle-ci
CA3021066C (fr) Compositions pharmaceutiques orales de nicotinamide
US9132092B1 (en) Pharmaceutical composition of doxycycline
JP2014508187A (ja) 選択的セロトニン再取り込み阻害薬の放出制御医薬組成物
WO2009024858A1 (fr) Forme posologique à libération contrôlée de galantamine
KR101990951B1 (ko) 리바스티그민 함유 서방출 의약조성물
KR20210109480A (ko) 벤즈이미다졸 유도체 화합물을 포함하는 약학적 조성물
CA2902665C (fr) Compositions pharmaceutiques de donepezil presentant un profil de dissolution in vitro ou des parametres pharmacocinetiques specifiques
JP2009525953A (ja) ジバルプロ酸及びその誘導体の徐放性製剤
TR2023000985A2 (tr) Kontrollü salim sağlayan propi̇veri̇n formülasyonu
WO2015150943A1 (fr) Composition pharmaceutique de ains et ppi ou sel de ces derniers

Legal Events

Date Code Title Description
STAA Information on the status of an ep patent application or granted ep patent

Free format text: STATUS: THE INTERNATIONAL PUBLICATION HAS BEEN MADE

PUAI Public reference made under article 153(3) epc to a published international application that has entered the european phase

Free format text: ORIGINAL CODE: 0009012

STAA Information on the status of an ep patent application or granted ep patent

Free format text: STATUS: REQUEST FOR EXAMINATION WAS MADE

17P Request for examination filed

Effective date: 20220517

AK Designated contracting states

Kind code of ref document: A1

Designated state(s): AL AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HR HU IE IS IT LI LT LU LV MC MK MT NL NO PL PT RO RS SE SI SK SM TR

DAV Request for validation of the european patent (deleted)
DAX Request for extension of the european patent (deleted)
A4 Supplementary search report drawn up and despatched

Effective date: 20230703

RIC1 Information provided on ipc code assigned before grant

Ipc: A61K 9/22 20060101ALI20230627BHEP

Ipc: A61K 9/20 20060101ALI20230627BHEP

Ipc: A61K 9/16 20060101ALI20230627BHEP

Ipc: A61K 9/50 20060101ALI20230627BHEP

Ipc: A61K 47/38 20060101ALI20230627BHEP

Ipc: A61P 13/10 20060101ALI20230627BHEP

Ipc: A61P 13/00 20060101ALI20230627BHEP

Ipc: A61K 31/445 20060101AFI20230627BHEP

P01 Opt-out of the competence of the unified patent court (upc) registered

Effective date: 20230708

STAA Information on the status of an ep patent application or granted ep patent

Free format text: STATUS: EXAMINATION IS IN PROGRESS

17Q First examination report despatched

Effective date: 20240314